Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
1. The overall objective response rate was 35.1% in patients with initial measurable disease, all of which were partial responses, ...
Tag: KRAS G12C
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)
Long-Term Outcomes of Sotorasib in KRAS-G12C Non–Small-Cell Lung Cancer
1. Sotorasib showed prolonged efficacy with a median OS of 12.5 months (33% at 24 months) and an ORR of ...
#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. Median progression-free survival was 5.6 ...
Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
1. Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. 2. Median progression-free survival ...
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
1. In patients with KRAS p.G12C mutated pancreatic cancer, 21% had a partial response, and 0% had a complete response. ...